TWI568441B - A lactobacillus reuteri gmnl-263 composition for controlling body weight and its use thereof - Google Patents

Description

Lactobacillus reuteri GMNL-263 composition for controlling body weight and use thereof

The present invention relates to a Lactobacillus isolate which is in the technical field of controlling body weight.

With the development of the city, obesity has gradually become a healthy killer often encountered by modern people. More and more studies have pointed out that obesity will increase the risk of new blood vessel diseases such as diabetes, cancer, gallbladder disease, hypertension, arteriosclerosis, etc. How to effectively reduce body fat and slow down obesity is a top priority.

Obesity is a body fat excess that is usually caused by changes in physiological or biochemical functions, which can significantly impair health. Fat usually includes neutral lipids, phospholipids and cholesterol. The increase in weight depends on the energy intake of the person being greater than the energy consumption. There are two types of obesity: (a) simple obesity, and (b) second obesity. Simple obesity can be divided into idiopathic obesity and acquired obesity, which can account for more than 95% of obesity. Congenital obesity is caused by a large number of fat cells and is common in childhood obesity. Acquired obesity is caused by the larger size of fat cells and is common in adulthood obesity. Secondary obesity, also known as symptomatic obesity, is usually caused by endocrine or metabolic diseases. Obesity is associated with several chronic diseases such as diabetes, cardiopathy, hypertension, stroke, biliary calculus, gout and certain cancers.

There are currently five strategies for treating obesity: diet, exercise, behavioral therapy, medication, and therapeutic operations. Depending on the patient's health risk factors, and the speed and effectiveness of weight loss, these strategies can be selected or combined to treat obese patients. The rate and effectiveness of weight loss are affected by factors such as age, height, family history and risk factors. The influence of one factor. The mechanisms of drug treatment include appetite suppression, increased energy expenditure, stimulation of fat movement, reduction of triglyceride glycerol synthesis, and inhibition of fat absorption. An example of such a drug is phenylpropanolamine (phenylpropanolamine, PPA), orlistat (XenicalTM), and sibutramine (ReductilTM). However, treating obesity with natural substances rather than drugs is a new trend.

Probiotics are beneficial intestinal bacteria. It has been reported that in addition to regulating immunity and intestinal health, it also has improved functions for hypertension, cancer and high cholesterol. In addition, current research shows that certain probiotics have the ability to regulate body weight and body fat for obese mice, and have efficacy for both live and dead bacteria. Based on previous studies, it is speculated that probiotics may have important functional ingredients. The applicant's previous case, US 8,298,526, found that Lactobacillus reuteri GMNL-263 can effectively improve the symptoms of type 1 diabetes. However, whether or not probiotics can effectively improve obesity symptoms or reduce body weight, and through which mechanism to improve obesity, has not been reported in the literature.

Because the research on probiotics before obesity is not extensive, it is urgent to find effective probiotics. Since 3T3-L1 pre-adipocytes have been widely used in the study of adipose tissue and its mechanism of action, this experiment used 3T3-L1 pre-adipocytes to explore the effects of lactic acid bacteria extracts on the synthesis of adipocytes, and has identified potential anti-obesity potential. The lactic acid bacteria Lactobacillus reuteri GMNL-263 (Lr263); further animal models were used to simulate obese rats, and the high-fat food was fed and matched with different doses of Lr263 dead bacteria and live bacteria.

It is an object of the present invention to provide a use of a probiotic for the preparation of a composition for weight loss or weight maintenance, wherein the probiotic comprises Lactobacillus reuteri GMNL-263 with accession number BCRC 910452 and CCCCC M 209263.

To achieve the foregoing object, the Lactobacillus reuteri GMNL-263 composition comprises at least one of a living bacteria, a dead bacteria, and an extract.

To achieve the foregoing object, the composition is a pharmaceutical composition, a food or a combination thereof; wherein the pharmaceutical composition may further comprise a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is in a dosage form for oral administration. Wherein the dosage form is selected from the group consisting of a solution, a suspension, an emulsion, a powder, a lozenge, a pill, a syrup, a buccal tablet, a tablet, a chewing gum, a thick paste, and a capsule, wherein the pharmaceutical The composition comprises at least one of 10 ⁵ to 10 ¹⁰ live bacteria, dead bacteria and extracts of Lactobacillus reuteri GMNL-263 at a daily dose. Wherein the food product may further comprise at least one probiotic selected from the group consisting of: lactobacillus sp. , Bifidobacterium sp. , Streptococcus sp. Yeasts, wherein the food product further comprises an edible material comprising water, fluid dairy, milk, concentrated milk, yogurt, yogurt, frozen yogurt, lactobacillus fermented beverage, milk powder, Ice cream, cheese, cheese, soy milk, fermented soy milk, vegetable juice, juice, sports drink, dessert, jelly, candy, baby food, health food, animal feed, Chinese herbal medicine or dietary supplement, wherein the food contains 10 ⁵ to 10 ¹⁰ At least one of the live bacteria, dead bacteria and extract of Lactobacillus reuteri GMNL-263.

A second object of the present invention is to provide a composition for the preparation of a composition for the treatment of obesity and a complication thereof, wherein the complication is selected from the group consisting of hypercholesterolemia, atherosclerosis, coronary heart disease and A group of fatty livers.

A second object of the present invention is to provide a composition for the purpose of the present invention for inhibiting fat synthesis, high overall fat, high visceral fat, high gonad fat, high total cholesterol concentration, high triglyceride lipid concentration, or high and low density. Use of a composition of lipoprotein/high density lipoprotein ratio (LDL/HDL).

Figure 1 shows the effect of Lr263 extract on the fat content of fat cells. (A) Oil Red O staining map (100X image). (B) Percentage of fat content, triple overlay, abc indicates significant difference, p < 0.05, Duncan analysis.

Figure 2 shows the effect of Lr263 on body weight. (A) is week 12; (B) is week 0-12.

Figure 3 shows the effect of Lr263 on body fat/body weight ratio.

Figure 4 shows the effect of Lr263 on visceral fat weight/body weight ratio.

Figure 5 shows the effect of Lr263 on gonad fat/body weight ratio.

Figure 6 shows the effect of Lr263 on liver function.

Figure 7 shows the effect of Lr263 on blood lipid levels.

Figure 8 shows the effect of Lr263 on the LDL/HDL ratio.

All of the technical and scientific terms described in this specification, unless otherwise defined, are intended to be common to those of ordinary skill in the art.

The present invention is a composition for treating obesity comprising Lactobacillus reuteri GMNL-263 with accession numbers BCRC 910452 and CCTCC M 209263. In addition, the present invention also relates to a novel use of the composition or the Lactobacillus for treating obesity, the mechanism of action of which is to inhibit the synthesis of fat, and to reduce the formation of oil droplets for the purpose of treating obesity.

Wherein the Lactobacillus isolate also comprises a subcultured progeny, or a mutant thereof, but still has the same characteristics as the species, genomic, or use (for inhibition of enterovirus) of the present invention.

The compositions described herein may include, but are not limited to, foods, beverages, health foods, animal water supplements, animal feed supplements, animal and human medical compositions, food supplements, beverage supplements, etc., suitable for use in the present invention. Application form.

The terms "treatment," "in therapy," and the like, mean delaying, ameliorating, reducing, or reversing a condition that is currently afflicting the condition of the patient or any condition associated with the condition and preventing the condition or any symptoms that are present. Methods.

The term "pharmaceutically acceptable" means that the substance or composition must be compatible with the other ingredients of the formulation and not deleterious to the patient.

The term "Cell Lyaste" may be a single extract obtained from a particular extraction step or series of extraction steps, or the extract may also be a combination of several extracts obtained from several separate extraction steps. These combined extracts are therefore also covered by the term "extract".

The composition of the present invention can be prepared into a composition suitable for use in the present invention by using the above-described Lactobacillus isolate and a pharmaceutically acceptable vehicle by techniques well known to those skilled in the art. shape. Wherein the dosage form comprises, but is not limited to, a solution, an emulsion, a suspension, a powder, a tablet, a pill, a lozenge, a tablet. (troche), chewing gum, capsules, and other dosage forms similar or suitable for use in the present invention.

Wherein the pharmaceutically acceptable carrier may comprise one or more agents selected from the group consisting of: solvents, emulsifiers, suspending agents, decomposers (decomposer), binding agent, excipient, stabilizing agent, chelating agent, diluent, gelling agent, preservative ), a lubricant, a surfactant, and other carriers similar or suitable for use in the present invention.

In the above composition, one or more dissolution aids, buffers, preservatives, coloring agents, perfumes, flavoring agents and the like which are usually used in the field of preparation may be appropriately added as needed.

In another preferred embodiment, the aforementioned composition provided by the present invention may further comprise an edible material to prepare a food product or a health care product. Wherein the edible material comprises, but is not limited to: water, fluid milk products, milk, concentrated milk; fermented milk, such as yogurt. , sour milk, frozen yogurt, lactic acid bacteria-fermented beverages; milk powder; ice cream; cream cheeses; Cheeses); soybean milk; fermented soybean milk; vegetable-fruit juices; juices; sports drinks; confectionery; jellys; Candies); infant formulas; health foods; animal feeds; Chinese herbals; dietary supplements.

In addition, the novel strains discovered by the present invention may be included in a composition together with other conventional strains.

Wherein the composition may further comprise at least one conventional probiotic selected from the group consisting of: lactobacillus sp. , Streptococcus sp. , Bifidobacterium Sp. ), yeast (yeasts).

Wherein the lactobacillus sp. includes, but is not limited to, lactobacillus lactis , lactobacillus acidophilus , lactobacillus helveticus , lactobacillus bifidus ), lactobacillus casei , Lactobacillus paracasei subsp. paracasei , Lactobacillus rhamnosus , Lactobacillus gasseri , Lactobacillus reuteri ( Lactobacillus reuteri ), Lactobacillus fermentum , or a combination thereof.

The Streptococcus sp. includes, but is not limited to, Streptococcus lactis , Streptococcus thermophilus , Streptococcus cremoris , or a combination thereof.

Wherein the conventional Bifidobacterium sp. includes, but is not limited to, Bifidobacterium breve , Bifidobacterium lactis , Bifidobacterium longum , and a double fork. Bifidobacterium bifidum , or a combination thereof.

Wherein the yeasts include but not limited to: Saccharomyces cereviseae , Candida kefyr , Saccharomyces florentimus , or a combination thereof.

Further, the present invention also provides a method or use of the aforementioned Lactobacillus for preparing a composition for weight loss or weight maintenance.

The composition provided by the present invention and the method thereof for weight loss or weight maintenance, and the administration route thereof are appropriately adjusted according to the needs, and are not particularly limited, and are preferably administered orally by an appropriate dosage form.

The present invention is exemplified by the following examples, but the present invention is not limited by the following examples. The drugs and biological materials used in the present invention are commercially available and are readily available. The following are only examples of available pipelines.

The present invention is exemplified by the following examples, but the present invention is not limited by the following examples.

The applicant (Jingyue Biotechnology Co., Ltd.) isolated more than 100 isolates from healthy adult gastrointestinal tract samples to establish an isolate strain library. The contact status, acquisition time, collector, and collector's contact information are listed in Table 1.

Lactobacillus which can treat obesity is selected from the strain library. The registration number, storage date and strain name of the Lactobacillus are shown in Table 2; among them, Lactobacillus reuteri GMNL-263 (hereinafter referred to as Lr263) For the published strains, the original documents and related information such as strain characteristics, storage certificates, survival test reports, etc., are included in the multinational patents.

Embodiment 1

Experimental materials: 3T3-L1 pre-adipocytes (BCRC 60159 purchased from Hsinchu Food Industry Research Institute, Taiwan), DMEM-high glucose, MRS medium (broth).

Experimental detection method: mainly refer to the method described by Park et al. (2011), slightly modified.

a. Preparation of lactic acid bacteria extract (Cell Lyaste):

1. The strain was obtained from the strain bank and taken out, and cultured for 18 hours via MRS medium.

2. The cultured bacterial solution was centrifuged at 2,700 rpm for 10 minutes, washed with PBS buffer, and the medium was removed to finally obtain a strain without residual medium.

3. The re-dissolution with PBS buffer solution strain, and the number of cells adjusted to 1 × ¹⁰ 10 cell / ml.

4. The adjusted bacterial solution is disrupted by ultrasonication, filtered through a 0.22 μm filter membrane, and stored at -20 ° C until use.

b. 3T3-L1 cell culture:

1. 3T3-L1 pre-adipocytes were cultured in DMEM (High Glucose) medium containing 10% calf serum (BS) and 1% antibiotic (PS), and the medium was changed every 2 to 3 days and subcultured once.

2. The whole cell count is 8×10 ⁴ cell/well, and the 24-well flat-bottom cell culture plate is implanted. After three days, the whole cell can be reached. After the medium is changed, the culture is continued for two days.

3. DMEM (high glucose) differentiation medium containing 10% FBS, 10 μg/mL insulin, 0.5 mM 3-isobutyl-1-methylxanthine and 1 μM dexamethasone was cultured for three days.

4. Then replace with DMEM (High Glucose) differentiation medium containing only 10% fetal bovine serum albumin (FBS), 1% antibiotic (PS) and 10μg/mL insulin, and change the medium every two days. After 14 days of culture, About 90% differentiate into mature fat cells.

c. Protein quantitative analysis:

1. After removing the cell culture medium, wash it three times with PBS buffer solution.

2. After the cells were detached from the plate with Trypsin, the cells were collected into PBS using PBS.

3. Centrifuge at 2,000 rpm for five minutes, remove the supernatant and add lysis buffer to rupture the cells.

4. Centrifuge at 14,000 rpm for 10 minutes, take the supernatant as a measurement sample, and dilute the Bio-Rad Protein assay five times. Then, mix 900 μl with 100 μl of the supernatant or standard BSA, and let stand for 5 minutes.

5. Determine the A ₅₉₅ wavelength.

Oil Red O staining method for measuring intracellular fats: Oil Red O is an oil-soluble dye that dyes the oil in the cytoplasm to a red color.

1. After removing the medium, gently rinse the cells three times with PBS buffer.

2. Add 200 μl of methanol to stand for one hour to fix the cells.

3. The oil red O stock solution was formulated into an oil red O working solution, and the washed cells were added to 200 μl of oil red O working solution for one hour.

4. After removing the staining solution, wash it three times with deionized water and then remove the water.

5. Take a photo with a microscope.

6. Add 500 μl of isopropanol to overnight, and after the dye is dissolved, measure the wavelength at 492 nm. Dividing the measured oil content by the protein content means that the amount of oil is contained in each cell.

Test results

The Lr263 extract was dissolved in PBS solution by ultrasonic vibration at a concentration of 1×10 ¹⁰ cell/ml, and the 3T3-L1 pre-adipocytes were treated with different concentrations of the cell extract to observe the effect on the differentiation of adipocytes.

After 22 days of culture, after the fat cells were stained with Oil Red O, the oil droplets were clearly observed (red part). From Figure 1A, it can be found that the concentration of Lr263 extract is increased, red The area of the oil droplets is reduced.

The fat cells were treated with 0.05 and 0.5% Lr263 extracts, and the fat oil drops were 68.5±16.0% and 32.1±5.6%, which inhibited the fat synthesis by about 30% and 70%. The highest concentration of 5% treated fraction has an ability to inhibit fat synthesis by about 90%, with a fat content of only 13.4 ± 1.6% (Fig. 1B).

Based on the above results, Lr263 extract can effectively inhibit the production of fat and fat in the differentiation process of fat cells, in other words, can inhibit the synthesis of fat. Therefore, from the results of in vitro tests, Lr263 is a lactic acid bacteria with anti-obesity potential.

Embodiment 2

Experimental procedure: The experiment was started with high-fat diet and lactic acid bacteria from the first day, and the mice were sacrificed after 12 weeks. Drinking water and food intake were recorded daily during the experiment; body weight changes and fasting blood glucose values were recorded weekly; oral glucose tolerance was detected every four weeks.

Preparation of lactic acid bacteria dead bacteria: Lactobacillus reuteri Lr263 was cultured in MRS medium and placed in a 37 ° C incubator. After 12 hours, the cells were washed twice with PBS and then placed in a water bath at 100 ° C for 20 minutes. After the addition of the cryoprotectant, the Lr263-containing lactic acid bacteria liquid was freeze-dried into a powder form in a freeze dryer.

The normal diet and high fat diet, the feed formula is detailed as follows:

Animal experiment: 5 weeks old male SD rats were purchased from Lesco (Taipei, Taiwan), raised in plastic cages, 10 in each group, controlled 12 hours day/night cycle, temperature 25 ± 1 ° C, free Drinking water and eating. After adjusting the experimental animals for one week, the experimental animals were randomly divided into the following eight groups according to their body weight.

1. Normal feed group: Give normal feed and feed 1ml of RO water every day.

2. Normal feed + Lr263 dead group: Give normal feed and feed Lr263 lactic acid bacteria every day (5×10 ⁹ cells/rat)

3. High fat diet group (HFD) (negative control group): high fat diet and 1 ml of RO water per day

4. HFD+Shirota dead (positive control group): High fat diet was administered and Shirota lactic acid bacteria (5×10 ⁹ cell/rat) were fed daily. Daisuke, a professor of microbiology at the Faculty of Medicine of Kyoto University in Japan, successfully cultivated a lactic acid bacteria that was beneficial to the human intestines in 1930, and later named it Lactobacillus casei strain Shirota as a positive control group.

5. High-fat diet + Lr263 lactic acid bacteria low-dose group: high-fat diet and daily feeding of Lr263 lactic acid bacteria (5 × 10 ⁵ cell / rat)

6. High-fat diet + Lr263 lactic acid bacteria in the middle dose group: high-fat diet and daily feeding of Lr263 lactic acid bacteria (5 × 10 ⁷ cell / rat)

7. High-fat diet + Lr263 lactic acid bacteria high-dose group: high-fat diet and daily feeding of Lr263 lactic acid bacteria (5 × 10 ⁹ cell / rat)

8. High-fat diet + Lr263 lactic acid bacteria live bacteria group: high-fat diet and daily Lr263 lactic acid bacteria (2 × 10 ⁹ cell / rat)

Statistical analysis: The data were analyzed by SPSS software. One-way analysis of variance (ANOVA) was used to test whether there was a significant difference between the experimental groups. If there is a significant difference (P<0.01), then the Duncan-type multivariate domain Duncan's new multiple range test for further analysis.

Test results:

A. The effect of Lr263 dead bacteria on body weight: After feeding in different groups, at the 12th week, the positive control group fed HFD+Shirota only showed a downward trend, but did not reach significant difference; in contrast, the case passed HFD+ After Lr263 low-dose group, HFD+Lr263 medium-dose group, HFD+Lr263 high-dose group, and HFD+Lr263 live group, the body weight was statistically significantly lower than that of HFD group. Two A, B, and Table 4), and the effect of weight loss in the middle dose group of dead bacteria is even better than that of the live bacteria group. These results demonstrate that Lr263 dead bacteria and live bacteria are effective in treating obesity and reducing weight.

The effect of B and Lr263 on body fat weight/body weight ratio: After feeding in different groups, at the 12th week, it was found that the HFD+Lr263 dead medium dose group, HFD+Lr263 dead bacteria high dose group, After feeding the HFD+Lr263 live bacteria group, the fat/body weight ratio was statistically significantly lower than that of the HFD group (Fig. 3). Among them, Lr263 was fed with dead bacteria, and the fat/body weight ratio showed a decreasing trend with the dose increase. The low, medium and high dose groups of HFD+Lr263 decreased by 21.6%, 24.8% and 31.0%, respectively, compared with the HFD group.

Effect of C and Lr263 on visceral fat weight/body weight ratio: After measuring the total fat weight/body weight ratio as described above, the visceral fat weight change at the 12th week was further examined. It was also found that after feeding the HFD+Lr263 dead medium dose group, the HFD+Lr263 dead bacteria high dose group, and the HFD+Lr263 live bacteria group, the visceral fat weight/body weight ratio was statistically significantly lower than that of the HFD group ( Figure 4). Among them, Lr263 was fed with dead bacteria, and the visceral fat weight/body weight ratio decreased with the increase of dose. The low, medium and high doses of HFD+Lr263 dead bacteria decreased by 20.9%, 23.2% and 31 respectively compared with HFD group. %.

D, Lr263 on the gonad fat weight / body weight ratio: After measuring the overall fat weight / body weight ratio, further examination of the change in gonad fat weight at the 12th week. It was also found that after feeding the HFD+Lr263 dead medium dose group, the HFD+Lr263 dead bacteria high dose group, and the HFD+Lr263 live bacteria group, the gonadal fat weight/body weight ratio was statistically significantly lower than that of the HFD group ( Figure 5). Among them, Lr263 was fed with dead bacteria, and the weight/weight ratio of gonadal fat decreased with the increase of dose. The low, medium and high dose groups of HFD+Lr263 decreased by 10.0%, 31.8% and 33.7, respectively, compared with HFD group. %.

Effects of E and Lr263 on liver function: After feeding in different groups, the aspartate aminotransferase (AST, U/L) and alanine groups in biochemical serum were detected at the 12th week. Transferase (ALT, U/L) values. Among them, after AST test, after HFD+Lr263 low-dose group, HFD+Lr263 high-dose group and HFD+Lr263 live group, the AST value was statistically significantly lower than that of HFD group. Six), while the HFD+Shirota group did not differ significantly. In addition, after ALT detection, it was found that the ALT values were compared with those of HFD+Lr263 low-dose group, HFD+Lr263 dead medium dose group, HFD+Lr263 dead bacteria high-dose group, and HFD+Lr263 live bacteria group. There was a statistically significant decrease in the group (Figure 6), while there was no significant difference in the HFD+Shirota group.

We were surprised to find that, regardless of AST or ALT values, Lr263 dead bacteria can achieve high doses of Lr263 live bacteria (2×10 ⁹ cell) in the case of low dose (5×10 ⁵ cell/ml/rat). /ml/rat) can achieve the effect, and the effect can even reach the same value as the normal feeding group.

Effect of F and Lr263 on blood lipid levels: After feeding in different groups, at the 12th week, total cholesterol (T-CHO, mg/dL) and triglyceride (TG) in biochemical serum lipids were detected. , mg/dL) value. After the total cholesterol test, the total cholesterol value was found after the low dose group of HFD+Lr263, the medium dose group of HFD+Lr263, the high dose group of HFD+Lr263, and the live group of HFD+Lr263. There was a statistically significant decrease in the HFD group (Figure 7). In addition, after the detection of triglyceride, it was found that after the low dose group of HFD+Lr263 dead bacteria, the medium dose group of HFD+Lr263 dead bacteria, the high dose group of HFD+Lr263 dead bacteria, and the live group of HFD+Lr263, the triglyceride was fed. There was also a statistically significant decrease in the number of fats compared to the HFD group (Figure 7).

We were also surprised to find that, regardless of the total cholesterol or triglyceride value, the Lr263 dead bacteria can achieve the same value as the normal feeding group at low doses (5×10 ⁵ cell/ml/rat). .

Effects of G and Lr263 on LDL/HDL ratio: Low-density lipoprotein/high-density lipoprotein (LDL/HDL) values were measured at week 12 after feeding in different groups. After testing, it was found that after LFD+Lr263 low-dose group, HFD+Lr263 dead medium dose group, HFD+Lr263 dead bacteria high-dose group, HFD+Lr263 live bacteria group, the LDL/HDL ratio was compared with HFD. There was a statistically significant decrease in the groups (Figure 8), while there was no significant difference in the HFD+Shirota group.

We were surprised to find that the Lr263 dead bacteria in the low dose (5 × 10 ⁵ cell / ml / rat), the effect is almost equivalent to the normal feeding group, and with the increase in dose LDL / HDL ratio The drop effect is more pronounced.

The above-mentioned multiple functions are in fact the statutory invention patents that fully meet the novelty and progressiveness. If you apply in accordance with the law, you are requested to approve the application for this invention patent to encourage invention.

【Biomaterial Storage】 Domestic registration information [please note according to the registration authority, date, number order]

1. The Bioresource Conservation and Research Center of the Hsinchu Food Industry Development Research Institute, the registration date is November 6, 2009, and the registration number is BCRC 910452.

Foreign deposit information [please note according to the country, organization, date, number order]

1. The China Type Culture Collection, the date of registration is November 13, 2009, and the registration number is CCTCC M 209263.

Claims (10)

Use of a probiotic for the preparation of a composition for reducing or maintaining the body weight of a high fat diet obese patient, wherein the probiotic comprises Lactobacillus reuteri GMNL-263 with accession numbers BCRC 910452 and CCCCC M 209263, the composition is a daily dose of 5 × 10 ^{5 -} 5 × 10 ⁷ L. reuteri, the L. reuteri is dead bacteria. Use of a probiotic as described in claim 1 for the preparation of a composition for weight loss or weight maintenance, wherein the composition is a pharmaceutical composition, a food or a combination thereof. Use of a probiotic as described in claim 3 for the preparation of a composition for weight loss or weight maintenance, wherein the pharmaceutical composition may further comprise a pharmaceutically acceptable carrier. The use of a probiotic as described in claim 3 for the preparation of a composition for weight loss or weight maintenance, wherein the pharmaceutical composition is in a dosage form for oral administration. Use of a probiotic as described in claim 5 for the preparation of a composition for weight loss or weight maintenance, wherein the dosage form is selected from the group consisting of a solution, a suspension, an emulsion, a powder, an ingot Agents, pills, syrups, buccal tablets, tablets, chewing gums, thick pastes and capsules. Use of a probiotic as described in claim 3 for the preparation of a composition for weight loss or weight maintenance, wherein the food product may further comprise at least one probiotic selected from the group consisting of Lactobacillus species ( lactobacillus sp.), Bifidus species (Bifidobacterium sp.), Streptococcus species (Streptococcus sp.) and yeasts (yeasts). The use of the probiotic according to claim 3, wherein the food product further comprises an edible material comprising water, fluid dairy, milk, concentrated. Milk, yogurt, yogurt, frozen Yogurt, Lactobacillus fermented beverage, milk powder, ice cream, cheese, cheese, soy milk, fermented soy milk, vegetable juice, juice, sports drink, dessert, jelly, candy, baby Food, health food, animal feed, Chinese herbal medicine or dietary supplements. Use of a probiotic for the preparation of a composition for the treatment of high fat diet obesity and its complications, wherein the probiotic comprises Lactobacillus reuteri GMNL-263 with accession numbers BCRC 910452 and CCTCC M 209263 The composition is a daily dose of 5 x 10 ^{5 -} 5 x 10 ⁷ Lactobacillus reuteri, which is a dead bacterium. The use of claim 11, wherein the complication is selected from the group consisting of hypercholesterolemia, atherosclerosis, coronary heart disease, and fatty liver. A probiotic for the production of fat-synthesis, high overall fat, high visceral fat, high gonadal fat, high total cholesterol, high triglyceride lipid concentration, or high and low density lipoprotein/high density in obesity patients with high fat diet Use of a composition of lipoprotein ratio (LDL/HDL), wherein the probiotic comprises Lactobacillus reuteri GMNL-263, having accession numbers BCRC 910452 and CCTCC M 209263, the composition being a daily dose 5 × 10 ^{5 -} 5 × 10 ⁷ Lactobacillus reuteri, the Lactobacillus reuteri is dead bacteria.